Advertisement
Table 1 Model parameter values
| Variable | Age group | Value (range) | Source |
|---|---|---|---|
| Population size | 0-2 | 63,025 | 2006 Census [42] |
| 3-4 | 42,260 | ||
| 5-17 | 322,670 | ||
| 18-24 | 203,500 | ||
| 25-54 | 975,875 | ||
| 55-64 | 237,795 | ||
| ≥65 | 271,455 | ||
| Total | 2,116,580 | ||
| Latent period (days) | All | 3 (2-4) | Tuite et al. 2010 [22] |
| Initial asymptomatic infectious period (in all infected individuals) (days) | All | 1 | Liao et al. 2010 [43] |
| Total duration of infectiousness (days) | All | 7 (5-7) | Tuite et al. 2010 [22]; De Serres [44] |
| Basic Reproduction number (R 0) | All | 1.4 (1.2-1.8) | Pourbohloul et al. 2009 [27] |
| Proportion of population with pre-existing immunity | ≥55 | 0.5 | Centers for Disease Control and Prevention 2009 [13]; Fisman et al. 2009 [6] |
| Vaccine efficacy | All | 0.9 (0.5-1) | Product Monograph Arepanrix(tm) H1N1 [45]; Waddington et al., 2010 [46] |
| Proportion of infected individuals who self-isolate | All | 0.1 (0.1-0.6) | Assumption |
| Mortality (per 100,000 infections) | 0-2 | 30 | Donaldson et al. 2009 [47] |
| 2-4 | 27 | ||
| 5-17 | 11 | ||
| 18-24 | 12 | ||
| 25-54 | 30 | ||
| 55-64 | 65 | ||
| ≥65 | 980 |
